# Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

> **NCT03173417** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beijing Immunochina Medical Science & Technology Co., Ltd.** · enrollment: 177 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** IM19 CAR-T
- **DRUG:** fludarabine and cyclophosphamide

## Key facts

- **NCT ID:** NCT03173417
- **Lead sponsor:** Beijing Immunochina Medical Science & Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2019-05-01
- **Final completion:** 2019-05-01
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03173417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03173417, "Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03173417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*